The direct-acting antiviral regimen of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r)±dasabuvir (DSV)±ribavirin (RBV) demonstrated high rates of sustained viral response at post-treatment week 12 (SVR12) in clinical trials for treatment of hepatitis C virus (HCV) genotypes (GT) 1 and 4. To confirm the effectiveness of this regimen in the real world, we conducted meta-analyses of published literature on 30 April 2016. FreemanTukey transformation determined the SVR rate within GTs 1a, 1b and 4, as well as specific SVR rates by cirrhosis or prior treatment experience status. Rates of virologic relapse, hepatic decompensation, drug discontinuation and serious adverse events were also analysed. In total, 20 cohorts across 12 countries were identified, totalling 5158 patients. The overall SVR12 rates were 96.8% (95% CI 95.8-97.7) for GT1 and 98.9% (95% CI 94.2-100) for GT4. For GT1a patients, the SVR rates were 94% and 97% for those with or without cirrhosis, and 94% overall. For GT1b patients, the SVR rates were 98% and 99% for those with or without cirrhosis, and 98% overall. The virologic relapse rate of GT1 patients was 1.3%, across 3524 patients in nine studies that reported this parameter. The rate of hepatic decompensation was less than 1% across five studies, including 3440 patients, 70% of which had cirrhosis. Conclusions: Real-world SVR12 rates for OBV/PTV/r±DSV±RBV were consistently high across HCV GT1 and four irrespective of cirrhosis status or prior HCV treatment experience, confirming effectiveness within a diverse patient population across multiple cohorts and countries. In contrast, analysis of real-world effectiveness of OBV/PTV/r±DSV-based regimens demonstrated an overall 97% SVR rate in patients with HCV GT1 or 4 infection, 28 which is equivalent to efficacy observed in phase 3 clinical trials.
| INTRODUCTION
Hepatitis C virus (HCV) is a global pathogen estimated to infect between 80 and 185 million people worldwide. 1, 2 Hepatitis C is a health burden because if it remains untreated, it can result in the development of cirrhosis and hepatocellular carcinoma (HCC); 3 at least a quarter of all cirrhosis and HCC is associated with chronic HCV infection. 4 Additionally, the risk of HCV-induced morbidities such as portal hypertension, hepatic decompensation and associated mortality 5, 6 suggests getting HCV treatment and achieving sustained virologic response (SVR) are critical. paritaprevir (codosed with ritonavir [PTV/r]; identified by AbbVie and Enanta), and dasabuvir (DSV) with or without ribavirin (RBV) has resulted in high SVR rates in clinical trials. [9] [10] [11] [12] rate of 97%. 13, 14 Phase 3b clinical study demonstrated 100% SVR12
for patients with GT1b and compensated cirrhosis after treatment with OBV/PTV/r+DSV without RBV, resulting in label and treatment guidelines updates for this population. 15 Patients with GT4 infection are recommended treatment with the 2-DAA combination of OBV/ PTV/r+RBV, which also resulted in high SVR rates in clinical trials. [16] [17] [18] Although treatment of HCV with DAA therapies has increased SVR rates and decreased side effects, 3, 19, 20 27 In contrast, analysis of real-world effectiveness of OBV/PTV/r±DSV-based regimens demonstrated an overall 97% SVR rate in patients with HCV GT1 or 4 infection, 28 which is equivalent to efficacy observed in phase 3 clinical trials.
Here, we explored the real-world effectiveness of OBV/PTV/ r±DSV±RBV for the treatment of HCV GT1 and 4 within 20 unique patient cohorts across 25 studies, encompassing a total of 5158 patients. Meta-analyses determined real-world rates of virologic relapse, hepatic decompensation, drug discontinuation, serious adverse event rates (SAEs) and SVR rates for patient sub-groups, including those with cirrhosis and prior treatment experience.
| METHODS

| Literature search
A literature search that combined terms and subject headings for "hepatitis C" with terms and subject headings related to the 2-DAA and 3-DAA regimens (OBV/PTV/r±DSV±RBV) was performed on 31 Table S1 .
| Literature screening
Titles and abstracts were screened against predefined selection criteria (Table S2) Table S3 . 
| Data extraction
| Meta-analysis and Freeman-Tukey transformation
Random-effects meta-analyses of proportions were performed using the DOC Data 2.0 software platform with the integrated R Project for Statistical Computing package metafor. All proportions were transformed using the Freeman-Tukey double arcsine transformation 29, 30 because many of the proportions being analysed were near the extremes of 0 and 1 (ie 100%). The double arcsine transformation prevents the confidence interval of a summary estimate of proportion from falling outside of the range of 0-1 (0%-100%). It also prevents individual estimates at the extremes of 0 or 1 from receiving undue weighting in meta-analysis. To determine the statistical heterogeneity between studies, the I 2 statistic was used. ability between studies is due to study and data heterogeneity rather than random chance.
For meta-analyses of patients with HCV GT1, seven studies (Tables   S3 and S4 ; studies 7, 8, 14, 15, 16, 20 and 23) included a small number of participants with GT4; however, the proportion was no more than 26%, and thus, these populations were considered primarily GT1. For analysis of SVR12 for GT1a, two studies (studies 3 and 11) reported SVR12 proportions but did not report the population denominator (ie the total number of persons with GT1a who had SVR12 measured).
These denominators were imputed based on the overall population denominator (ie the overall number of persons in the study who were GT1a, irrespective of whether they had SVR12 measured), and the pro- 
| Role of the funding source
AbbVie sponsored the study, contributed to its design, the collection, analysis and interpretation of the data, and participated in the writing, review and approval of the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit the publication. 
| RESULTS
| Patient population and primary data sources
| Analysis of sustained virologic response by patient subgroups
Sustained virologic response by patient subgroups can be seen in Figure 2 . F I G U R E 1 Real-world SVR rates from primary studies. Each primary publication that reported SVR is shown here. There were 25 primary publications used for meta-analysis in this study; only 19 were used to calculate SVR due to cohort overlap or publications that did not report SVR. Corresponding study details for this figure are shown in were not included in the off-label treated group; those patients are discussed separately below.
| Analysis of safety and adverse events
Overall, in GT1 patients, 3.12% (95% CI, 2.49-3.90) of 2370 patients across seven studies experienced at least one serious adverse event ([SAE]; Table 1 ). Study drug was discontinued by 2.50% (95% CI, 2.10-2.96) of the 5170 GT1 patients in which data were available. Drug discontinuation was the only safety metric where data were available specifically for patients with GT4 infection. Among 42 patients for which data were available in this population, there was no discontinuation. For 3440 patients where data were reported, only 0.96% (95% CI, 0.68-1.34) of patients experienced hepatic decompensation; of note, 70% of these 3440 patients had cirrhosis. Overall, the virologic relapse rate across 3524 GT1-infected patients in nine studies was 
| Analysis of patients with renal disease or ChildPugh B cirrhosis
The OBV/PTV/r±DSV regimen does not require dose modification for those with ESRD, with or without dialysis, 32 Child-Pugh B cirrhosis, of which only one patient (2.6%) experienced this event. 
| Statistical heterogeneity
| DISCUSSION
Real-world evidence can provide insights into the effectiveness and safety of therapeutic regimens in a broader patient population and a more diverse clinical setting. This is critical because it is not unu- The real-world relapse rate here was still low at just above 1% across nine studies and over 3500 patients, consistent with the relapse rate for GT1 patients observed in clinical trials (0.8%).
35
Hepatitis C virus Subtype 1b is the most prevalent HCV infection worldwide, and thus, the largest subset of real-world patients treated with OBV/PTV/r+DSV±RBV (n=1750) fell into that group. Ninetyeight per cent of GT1b patients achieved SVR, with no appreciable difference in effectiveness between those with or without cirrhosis, a finding consistent with clinical trials in this population. 13 Patients with GT1a had a lower SVR rate compared to those with GT1b or GT4. This is not unexpected; in the era of DAA-based HCV therapies, patients with HCV GT1a have been more difficult to cure than those with GT1b and GT4, primarily due to the development of resistance. 36 Additionally, the presence of cirrhosis had a larger impact on SVR rate for GT1a than for GT1b or GT4; those with GT1a infection and cirrhosis had an overall SVR rate of more than 2% lower than their counterparts without cirrhosis. Nonetheless, the SVR of patients with GT1a infection, regardless of cirrhosis status, remained high (≥94%). Other factors that influence patients' ability to achieve SVR are serious adverse events (SAEs), especially those leading to drug discontinuation. Within the two placebo-controlled clinical trials designed to study safety, the reported rates of SAEs for patients treated with OBV/ PTV/r±DSV±RBV were 2.3 and 2.6 per cent. 33, 34 Here, the observed rate across seven studies was similar, at just above 3%, despite a high percentage of cirrhotic patients. Notably, the rate of drug discontinuation remained low (2.5%) within a population of over 5000 patients. A low death rate was also observed (0.5%) considering the high percentage of patients with cirrhosis. While mortality was a reported outcome for nearly 4700 patients, high variation in follow-up time between studies made it difficult to determine whether deaths occurred during treatment and the standard 12-week post-treatment period of clinical trials, or during extended 24-to 36-week post-treatment follow-up periods observed in some studies.
Although the presence of cirrhosis had little impact on the effectiveness of OBV/PTV/r±DSV±RBV, hepatic decompensation is an added risk for patients in that population. Estimated rates of annual hepatic decompensation for patients with compensated cirrhosis are 5%-7% overall, 40, 41 with the potential for higher rates among those undergoing treatment with DAAs. 42 Less than 1% rate of hepatic decompensation was observed across more than 3400 patients within cohorts that reported this event, suggesting that treatment of GT1 patients with OBV/PTV/r±DSV±RBV does not increase risk for decompensation. Documented manifestations of decompensation were available for 23 patients; there were eight patients with variceal bleeding, eight with ascites, six with hepatic encephalopathy and one patient that exhibited multiple signs. It is important to note that while most studies did not report specific event rates for cirrhotic patients, about 70% of these 3440 patients had cirrhosis (some with decompensated cirrhosis, despite contraindication), meaning the true rate of hepatic decompensation in the cirrhotic subpopulation could be closer to 1.37% (or slightly higher, depending on subsequent follow-up), assuming all patients that experienced decompensation had cirrhosis.
The potential for drug-induced liver damage cannot be ruled out, particularly for patients whose decompensation is reversed upon drug discontinuation, which could occur in rare cases of decompensation events among those patients without a history of cirrhosis. However, error; however, variability in study design and outcome reporting can also impact data heterogeneity. In this meta-analysis, many of the safety outcome analyses had considerable heterogeneity as measured by the I 2 statistic; much of the observed heterogeneity seen within safety outcomes can likely be attributed to the small number included studies, and variability in results and reporting between studies. Given that these primary studies were real-world observational cohorts, underlying differences in patient characteristics, study design and methods may have also contributed to statistical and clinical heterogeneity; however, such heterogeneity is difficult to evaluate due to lack of detailed available data from each individual source. In this study, only the SVR analyses of GT1a patients and GT1 patients with cirrhosis exhibited considerable heterogeneity (I 2 ≥50%). However, the results for SVR12 (particularly for GT1-infected patients) can be considered robust, as they include more than 5000 patients, and the associated confidence intervals had narrow ranges.
In summary, the present meta-analysis of real-world data for OBV/ PTV/r±DSV±RBV treatment of patients with HCV GT1 or 4 infection from over 5000 patients demonstrated high effectiveness and a safety profile similar to that observed in phase 3 clinical studies.
